Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Recruiting · NCT02926690 · Registry updated 2026-02-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-02-25 | NCT02926690 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OncoTherapy Science, Inc. | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center | Lebanon | United States | 1 |
| Emory University, Winship Cancer Institute | Atlanta | United States | 1 |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | United States | 31 |
| Kapi'olani Medical Center for Women & Children | Honolulu | United States | 4 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 3 |
| Norwalk Hospital | Norwalk | United States | 43 |
| Weill Cornell Medicine | NewYork-Presbyterian | New York | United States | 1 |